MiniMed Group, Inc.
- MMED ยท Nasdaq
- Surgical & Medical Instruments & Apparatus
- Northridge, CA
- 8,000 employees
- CIK 0002062583
Updated from SEC filings through
Top things to know
Executives
-
Que Dallara Chief Executive Officer 4, 2026-08-04 -
Chad Spooner EVP, Chief Financial Officer 4, 2026-07-29 -
Gillian Chandrasena SVP, Chief HR Officer 4, 2026-07-29 - John Gyurci VP, Chief Accounting Officer 4, 2026-07-06
- Christopher Eso President 3, 2026-03-05
- Sheila A. Denton SVP, Gen. Counsel & Corp. Sec. 4, 2026-10-05
What leadership is saying
“MiniMed delivered an excellent start to our fiscal year, with accelerating U.S. growth, continued double-digit international growth, and strong execution across our innovation pipeline”
Earnings press release (8-K Ex. 99.1), filed September 1, 2026
MiniMed Group, Inc. is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in Northridge, CA. It trades as MMED on Nasdaq. Revenue was $3.1B in the fiscal year ending April 24, 2026, +14.3% from the year before. It reported about 8,000 employees. Que Dallara is Chief Executive Officer.
Five-year financials
| Metric | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Revenue | $3.1B 10-K, 2026-06-29 | $2.7B 10-K, 2026-06-29 | $2.5B 10-K, 2026-06-29 |
| Operating income | -$190M 10-K, 2026-06-29 | -$146M 10-K, 2026-06-29 | -$69.0M 10-K, 2026-06-29 |
| SG&A | $1.2B 10-K, 2026-06-29 | $1.1B 10-K, 2026-06-29 | $1.1B 10-K, 2026-06-29 |
| Net income | -$333M 10-K, 2026-06-29 | -$213M 10-K, 2026-06-29 | -$112M 10-K, 2026-06-29 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Que Dallara CEO, MiniMed, Independent Board Director | Chief Executive Officer | 4, 2026-08-04 |
| Chad Spooner CFO, MiniMed | EVP, Chief Financial Officer | 4, 2026-07-29 |
| Gillian Chandrasena CHRO | SVP, Chief HR Officer | 4, 2026-07-29 |
| John Gyurci VP Chief Accounting Officer at MiniMed Group, Inc. (Nasdaq: MMED) | VP, Chief Accounting Officer | 4, 2026-07-06 |
| Christopher Eso | President | 3, 2026-03-05 |
| Sheila A. Denton | SVP, Gen. Counsel & Corp. Sec. | 4, 2026-10-05 |
 Ali Dianaty | EVP Ch. Prod. & Tech Officer | 4, 2026-08-04 |
| Kevin E. Lofton | Board member (per proxy) bio: Chair of the Board | DEF 14A, 2026-08-21 |
What MiniMed Group, Inc. does
We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes.
Shares and governance
| Shares outstanding | 281.3 million (as of September 3, 2026) | 10-Q, September 8, 2026 |
|---|---|---|
| Public float | $0 (as of April 24, 2026) | 10-K, June 29, 2026 |
| Reportable segments | 1 (period ending July 31, 2026) | S-4, September 14, 2026 |
| Latest proxy statement | Meeting October 9, 2026 (filed August 21, 2026) | DEF 14A, August 21, 2026 |
| Auditor | PricewaterhouseCoopers LLP (Minneapolis, Minnesota) | Latest 10-K |
Recent 8-K events
- 8-K filed 2026-10-16
- Item 5.01 Changes in control of registrant
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-10-13
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-09-01
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-05
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-06-29
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.08 Item 5.08
- Item 8.01 Other events
- 8-K filed 2026-06-03
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-05-18
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-04-27
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-03-27
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-03-25
- Item 7.01 Regulation FD disclosure
Frequently asked questions about MiniMed Group, Inc.
- What does MiniMed Group, Inc. do?
- In its own words, from Item 1 of its 10-K: "We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes."
- What is MiniMed Group, Inc.'s revenue?
- $3.1B for the fiscal year ending April 24, 2026, from its 10-K filed June 29, 2026.
- Is MiniMed Group, Inc. profitable?
- MiniMed Group, Inc. reported net income of -$333M for the fiscal year ending April 24, 2026.
- How many employees does MiniMed Group, Inc. have?
- About 8,000 as of April 24, 2026, as stated in its annual report.
- Who is the CEO of MiniMed Group, Inc.?
- Que Dallara, Chief Executive Officer, as named in a 4 filed August 4, 2026.
- Who is the CFO of MiniMed Group, Inc.?
- Chad Spooner, EVP, Chief Financial Officer, as named in a 4 filed July 29, 2026.
- Where is MiniMed Group, Inc. headquartered?
- Northridge, CA.
- What is MiniMed Group, Inc.'s stock ticker?
- MMED, MMEDV on Nasdaq.
- What industry is MiniMed Group, Inc. in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is MiniMed Group, Inc.'s website?
- minimed.com. Investor relations: https://investors.minimed.com.
- When does MiniMed Group, Inc. report earnings next?
- November 24, 2026 at 08:30. Source: ir_events.
- Is MiniMed Group, Inc. a public company?
- Yes. MiniMed Group, Inc. files with the SEC under CIK 0002062583 and trades as MMED.
- Who audits MiniMed Group, Inc.?
- PricewaterhouseCoopers LLP, Minneapolis, Minnesota, as named in its latest annual report (10-K).
- How many shares of MiniMed Group, Inc. are outstanding?
- 281.3 million shares as of September 3, 2026, from its 10-Q filed September 8, 2026.
- What is MiniMed Group, Inc.'s public float?
- $0 as of April 24, 2026, as reported on the cover of its 10-K filed June 29, 2026.
- How many business segments does MiniMed Group, Inc. report?
- 1 reportable segment for the period ending July 31, 2026, from its S-4 filed September 14, 2026.
- When is MiniMed Group, Inc.'s annual shareholder meeting?
- October 9, 2026, per its proxy statement (DEF 14A) filed August 21, 2026.